Sarcomeric dysfunction plays a central role in reduced cardiac pump function in heart failure. This review focuses on the alterations in sarcomeric proteins in diseased myocardium that range from altered isoform expression to post-translational protein changes such as proteolysis and phosphorylation. Recent studies in animal models of heart failure and human failing myocardium converge and indicate that sarcomeric dysfunction, including altered maximum force development, Ca2+sensitivity, and increased passive stiffness, largely originates from altered protein phosphorylation, caused by neurohumoral-induced alterations in the kinase-phosphatase balance inside the cardiomyocytes. Novel therapies, which specifically target phosphorylation sites within sarcomeric proteins or the kinases and phosphatases involved, might improve cardiac function in heart failure.

, , ,
doi.org/10.1093/cvr/cvm079, hdl.handle.net/1765/29146
Cardiovascular Research
Erasmus MC: University Medical Center Rotterdam

Hamdani, N, Kooij, V, van Dijk, S.J, Merkus, D, Paulus, W.J, Remedios, C.D, … van der Velden, J. (2008). Sarcomeric dysfunction in heart failure. Cardiovascular Research (Vol. 77, pp. 649–658). doi:10.1093/cvr/cvm079